EGFR and Skin rash: Furthermore, retrospective analyses of two phase 3 NSCLC trials show a positive correlation between rash and treatment effect on survival: the BR.21 trial12 of erlotinib and the FLEX trial11 of cetuximab, an anti-EGFR antibody, when added to first-line chemotherapy.